Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?

Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?

High phosphate intake is known to aggravate renal osteodystrophy along various pathogenetic pathways. Recent studies have raised the possibility that dysregulation of the osteocyte Wnt/β-catenin signaling pathway is also involved in chronic kidney disease (CKD)-related bone disease. We investigated...

Full description

Bibliographic Details
Main Authors:	Juliana C Ferreira, Guaraciaba O Ferrari, Katia R Neves, Raquel T Cavallari, Wagner V Dominguez, Luciene M Dos Reis, Fabiana G Graciolli, Elizabeth C Oliveira, Shiguang Liu, Yves Sabbagh, Vanda Jorgetti, Susan Schiavi, Rosa M A Moysés
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24236156/?tool=EBI

Similar Items

Adynamic bone disease
by: Ana Paula Santana Gueiros, et al.
Published: (2021-12-01)

Adynamic bone disease: Revisited
by: Sonia Sharma, et al.
Published: (2022-01-01)

Is Adynamic Bone Always a Disease? Lessons from Patients with Chronic Kidney Disease
by: Eman Nagy, et al.
Published: (2022-11-01)

The Protein-Independent Role of Phosphate in the Progression of Chronic Kidney Disease
by: Irene Faria Duayer, et al.
Published: (2021-07-01)

On the welfare significance of national product in adynamic economy
by: Weitzman, Martin L.
Published: (2011)

Study on the Effect of Low Calcium Dialysate on Biochemical Profile of Adynamic Bone Disease in Patients on Maintenance Hemodialysis
by: Suman Sethi, et al.
Published: (2023-01-01)

The Role of Sclerostin in Bone Diseases
by: Elias S. Vasiliadis, et al.
Published: (2022-02-01)

Adynamic response to cold pain reflects dysautonomia in type 1 diabetes and polyneuropathy
by: Thomas Arendt Nielsen, et al.
Published: (2023-07-01)

ADYNAMIC ANALYSIS OF TRUST IN CUSTOMER-BANK RELATIONSHIP:A RETROSPECTIVE CASESTUDIES APPROACH
by: Abdelmajid AMINE, et al.
Published: (2010-08-01)

Phosphorus is associated with coronary artery disease in patients with preserved renal function.
by: Ana Ludimila Cancela, et al.
Published: (2012-01-01)

The Role of Sclerostin in Rheumatic Diseases: A Review
by: Łukasz Jaśkiewicz, et al.
Published: (2023-09-01)

Lifelong genetically lowered sclerostin and risk of cardiovascular disease
by: Bovijn, J, et al.
Published: (2019)

Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
by: Stéphanie Fabre, et al.
Published: (2020-10-01)

A prospective study of the influence of the skeleton on calcium mass transfer during hemodialysis.
by: Patricia Taschner Goldenstein, et al.
Published: (2018-01-01)

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
by: Maarten van Dinther, et al.
Published: (2013-01-01)

Adynamic Graciloplasty for Faecal Incontinence in an Adult after Anal Atresia Correction in Infancy – a Case Report
by: Narimantas Evaldas Samalavicius, et al.
Published: (2020-12-01)

Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
by: Daniel Cejka
Published: (2021-11-01)

Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis.
by: Luciene P Magalhães, et al.
Published: (2017-01-01)

Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes
by: Alcalde-Herraiz, M, et al.
Published: (2024)

Sclerostin and Vascular Pathophysiology
by: Antonino Catalano, et al.
Published: (2020-07-01)

Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease
by: Alaa A. Omran, et al.
Published: (2022-06-01)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
by: Fangli Zhou, et al.
Published: (2021-08-01)

Sclerostin─A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?
by: Magdalena Jankowska, et al.
Published: (2017-05-01)

The Role of Sclerostin in Bone and Ectopic Calcification
by: Annelies De Maré, et al.
Published: (2020-04-01)

Bone plasticity in response to exercise is sex-dependent in rats.
by: Wagner S Vicente, et al.
Published: (2013-01-01)

A Rare Case of Bilateral Flank Pain: Anterior Nutcracker Syndrome and Post-pregnancy Hydronephrosis due to Adynamic Ureteral Segment
by: Mehmet Mert, et al.
Published: (2022-10-01)

Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease
by: Yadav, A, et al.
Published: (2018)

Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
by: Vladimir Gerov, et al.
Published: (2023-07-01)

Drug discovery of sclerostin inhibitors
by: Sifan Yu, et al.
Published: (2022-05-01)

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
by: Karina E. Pigeaud, et al.
Published: (2023-04-01)

Bone disease in newly diagnosed lupus nephritis patients.
by: Aline Lázara Resende, et al.
Published: (2014-01-01)

Analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory biomarkers in chronic kidney disease: impact of parathyroidectomy
by: Andre Kakinoki Teng, et al.
Published: (2024-04-01)

Plasma sclerostin level in multiple myeloma: Correlations with disease features and international staging system
by: Noor Hasan Baiee, et al.
Published: (2022-01-01)

Serum sclerostin levels in rheumatoid arthritis and correlation with disease activity and bone mineral density
by: Urmila Dhakad, et al.
Published: (2019-01-01)

Circulating level and tissue distribution of sclerostin in calcified mitral valves of rheumatic heart disease
by: S. Mukhopadhyay, et al.
Published: (2017-11-01)

Treatment of Osteoporosis in Chronic Kidney Disease
by: Fellype Carvalho Barreto, et al.

Antitumor Effect of Sclerostin against Osteosarcoma
by: Hirokazu Ideta, et al.
Published: (2021-11-01)

Sclerostin: From Molecule to Clinical Biomarker
by: Ahmed Omran, et al.
Published: (2022-04-01)

Positive and Negative Regulators of Sclerostin Expression
by: Rina Iwamoto, et al.
Published: (2022-04-01)

Sclerostin as a Putative Myokine in Sarcopenia
by: Hyon-Seung Yi
Published: (2022-06-01)